Percutaneous delivery of carbamazepine and selected N-alkyl and N-hydroxyalkyl analogues

International Journal of Pharmaceutics

Volumn 279, Issue 1-2, 2004, Pages 59-66

  Fourie, L ^a   Breytenbach, J C ^a   Du Plessis, J ^a   Goosen, C ^a   Swart, H ^a   Hadgraft, J ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Carbamazepine; N alkyl analogues; N hydroxyalkyl analogues; Percutaneous delivery; Transdermal

Indexed keywords

CARBAMAZEPINE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN TISSUE; LIPOPHILICITY; MELTING POINT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; PERMEABILITY; SKIN ABSORPTION; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 3242754953     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.04.007     Document Type: Article

References (14)

1. Amidon, G.L. 1981. Drug derivatisation as a means of solubilisation: physicochemical and biomedical strategies. In: Yalkowsky, S.H. (Ed.), Techniques of Solubilisation of Drugs. Marcell Dekker, New York, pp. 183-211.
2. Beckett, A.H. 1982. Mechanism of penetration of drugs into the skin. In: Brandau, R., Lippold, B.H. (Eds.), Proceedings of the First International Symposium of Dermal and Transdermal Absorption from Munich, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 12-14 January, 1981, pp. 154-170.
3. Bonina F., Puglia C., Barbuzzi T., De Caprariis P., Palagiano F., Rimoli M.G., Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen. Euro. J. Pharm. Sci. 14:2001;123-134
4. Flynn, G. L. 1993. Topical and transdermal delivery: provinces of realism. In: Gruny, R., Teuber, A. (Eds.), Proceedings of the Second International Symposium of the International Association for Pharmaceutical Technology (APV) Frankfurt of the Dermal and Transdermal Drug Delivery: New Insights and Perspectives. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 11-13 November 1991, pp. 33-66.
5. Goosen C., Laing T.J., Du Plessis J., Goosen T.C., Lu G., Flynn G.L. Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs. Pharm. Res. 19:2002;434-439
6. Guy, R.H., Hadgraft, J., 1992. Percutaneous penetration enhancement: physicochemical considerations and implications for prodrug design. In: Sloan, K.B. (Ed.), Prodrugs: Topical and Ocular Drug Delivery, Marcel Dekker, New York, pp. 1-16.
7. Hadgraft, J., Wolff, M. 1993. Physicochemical and pharmacokinetic parameters affecting percutaneous absorption. In Gurny, R., Teuber, A. (Eds.), Proceedings of the Second International Symposium of the International Association for Pharmaceutical Technology (APV) Frankfurt of the Dermal and Transdermal Drug Delivery: New Insights and Perspectives, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 11-13 November 1991, pp. 161-172.
8. Le B.H., Lippold B.C. Influence of physicochemical properties of homologous esters of nicotinic acid on skin permeability and maximum flux. Int. J. Pharm. 124:1995;285-292
9. McNamara, J.O. 1996. Drugs effective in the therapy of epilepsies. In: Hardman, J.G., Limbird, L.E. (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, ninth edition. McGraw-Hill, New York, pp. 461-486.
10. Naik A., Kalia Y.N., Guy R.H. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today. 3:2000;318-325
11. Parikh N.H., Babar A., Plakogiannis F.M. Transdermal therapeutic systems. Pharm. Acta Helv. 59:1984;290-292
12. Pefile S., Smith E.W. Transdermal drug delivery: vehicle design and formulation. S. Afr. J. Sci. 93:1997;147-158
13. Sloan K.B. Prodrugs for dermal delivery. Adv. Drug Del. Rev. 3:1989;67-101
14. Williams A.C., Barry B.W. Penetration enhancers. Adv. Drug Del. Rev. 56:2004;603-618